60 Degrees Pharmaceuticals Inc (SXTP) Q1 2026 Earnings Call Transcript

Why It Matters

The data positions United Therapeutics to dominate two high‑growth pulmonary markets, unlocking multibillion‑dollar revenue streams and reshaping treatment standards for PAH and IPF.

Key Takeaways

• Q1 revenue $782M despite winter slowdown.
• Tyvaso DPI up 9% YoY, $458M sales.
• Ralinepag cut disease progression threefold in PAH.
• IPF supplemental NDA filing planned by summer 2026.
• RALDPI Phase I to start by year‑end.

Pulse Analysis

United Therapeutics is leveraging a rare convergence of clinical success and market timing in the pulmonary therapeutic space. The robust Phase III outcomes for ralinepag, which demonstrated a threefold reduction in PAH disease progression, not only surpass existing prostacyclin agents but also set a new efficacy benchmark that could shift clinicians toward earlier, once‑daily oral therapy. Coupled with Tyvaso’s proven inhaled platform, the company now commands a dual‑track pipeline that addresses both vascular and fibrotic lung diseases, a combination that few competitors can match.

On the commercial front, Tyvaso’s dry‑powder inhaler (DPI) generated $458 million in Q1 revenue, reflecting a 9% year‑over‑year increase driven by higher patient demand and expanded prescriber reach. Despite a temporary dip in nebulized sales, the launch of higher‑dose capsules and combination kits has sustained shipment growth across five consecutive months. The upcoming supplemental NDA for Tyvaso in IPF, slated for summer filing, positions United Therapeutics to capture a sizable share of a market where current therapies offer limited functional improvement, especially given the drug’s reported >100 mL FVC gain.

Strategically, United Therapeutics is executing a "multiple shots on goal" approach, advancing RALDPI—a novel inhaled ralinepag formulation—into Phase I while scaling manufacturing capacity at both MannKind and its new North Carolina DPI facility. This diversified formulation strategy, spanning oral, DPI, and soft‑mist inhaler formats, aims to maximize addressable patient populations across PAH, IPF, PH‑ILD, and PPF. Financial guidance anticipates a $4 billion run‑rate by 2027, with the combined impact of ralinepag and Tyvaso potentially doubling that figure, underscoring a compelling growth narrative for investors.